40 research outputs found
Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review
: Introduction: In recent years, the treatment landscape of metastatic renal cell carcinoma (mRCC) has been improved using immune-checkpoint inhibitors (ICI). Nevertheless, the number of patients experiencing clinical benefit from immunotherapy is still limited, while others obtain more benefit from tyrosine kinase inhibitors (TKI). The identification of prognostic and predictive factors would be crucial to better select patients most likely to benefit from immunotherapy among the other potentially available therapeutic options.Areas covered: This systematic review summarizes the current knowledge (2010-2019) on molecular prognostic and predictive biomarkers, assessed in peripheral blood and/or from tumor tissue, in mRCC patients treated with ICI.Expert opinion: Among all the biomarkers analyzed, PD-L1 expression on tumor tissue is the most studied. It has an unfavorable prognostic role for patients treated with TKI, which seems to be overcome by ICI-based combinations. Nevertheless, no clear predictive role of immunotherapy efficacy has been observed for PD-L1 in mRCC. Emerging evidence regarding pro-angiogenic or pro-immunogenic genomic and transcriptomic signatures suggests a potential predictive role in patients treated with ICI-based combinations. The rationale for TKI-ICI combinations is based on tumor microenvironment and genomic background, which represent the target of these two main therapeutic options for mRCC
Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer
Background In patients with RAS wild-type (WT)
metastatic colorectal cancer (mCRC), the role of
maintenance therapy after first-line treatment with
chemotherapy plus antiepidermal growth factor receptor
(EGFR) monoclonal antibodies (MoAb) is still an object of
debate.
Methods We assessed the efficacy and safety of
regorafenib as a switch maintenance strategy after
upfront 5-fluorouracil-based chemotherapy plus an anti-
EGFR MoAb in patients with RAS WT mCRC. RAVELLO
was a phase III, international, double-blind, placebocontrolled,
academic trial. The primary endpoint was
progression-free survival (PFS). Secondary endpoints
included overall survival and toxicity. Regorafenib or
placebo were administered daily for 3 weeks of 4-week
cycle until disease progression or unacceptable toxicity,
up to 24 months.
Results The study was stopped prematurely due to
slow accrual and lack of funding after the randomisation
of 21 patients: 11 in the regorafenib arm and 10 in
the placebo arm. The small sample size precludes
any statistical analysis. Toxicity was acceptable and
consistent with the known regorafenib safety profile.
Median PFS was similar in the two arms. However,
a subgroup of patients treated with regorafenib
experienced a remarkably long PFS. Three patients
were progression free at 9 months in the regorafenib
arm versus one patient in the placebo arm, whereas at
12 months two regorafenib-treated patients were still
progression free versus none in the placebo arm.
Conclusion RAVELLO trial demonstrated that
growing financial and bureaucratic hurdles affect the
feasibility of independent academic research. Although
stopped prematurely and within the limited sample
size, RAVELLO suggests that regorafenib has not a major activity in maintenance setting after upfront
chemotherapy and anti-EGFR MoAb. However, a
subgroup of patients experienced a remarkable long
PFS, indicating that a better refinement of the patient
population would help to identify subjects that might
benefit from a regorafenib personalised approach in the
switch maintenance settin
Toward Targeted Therapies in Oesophageal Cancers: An Overview
Oesophageal cancer is one of the leading causes of cancer-related death worldwide. Oesophageal cancer occurs as squamous cell carcinoma (ESCC) or adenocarcinoma (EAC). Prognosis for patients with either ESCC or EAC is poor, with less than 20% of patients surviving more than 5 years after diagnosis. A major progress has been made in the development of biomarker-driven targeted therapies against breast and lung cancers, as well as melanoma. However, precision oncology for patients with oesophageal cancer is still virtually non-existent. In this review, we outline the recent advances in oesophageal cancer profiling and clinical trials based on targeted therapies in this disease.info:eu-repo/semantics/publishe
State of the Art of Optical Switching Technology for All-Optical Networks
All-optical switching fabrics will be a significant breakthrough in order to relieve the capacity bottleneck of electronic-switched networks. These devices allow switching traffic directly in the optical domain, avoiding the need of several optical-to-electrical-to-optical conversions. In this paper, the state of the art of optical switching fabrics is reviewed, by outlining the main technologies that are under development. Moreover, some possible applications and performance data are summarized, based on a market analysis that we carried out in the latest months. We believe that this review is valuable to researchers envisaging new all-optical switching network architectures for telecommunications networks of the future
Node Architecture Design for All-Optical IP Packet Switching
In order to support efficiently the fast-growing demand for transmission capacity, optical packet-switched systems seem to be strong candidates as they allow fast dynamic allocation of WDM channels combined with a high degree of statistical resource sharing. In this work, we propose the architecture of an input/shared-buffered optical packet switching node, for all-optical switching of IP traffic flows. Since a limited hardware complexity is a key requirement for all-optical switches, due to the high cost of optical components, different node configurations are compared in order to evaluate the effect of a hardwarecomplexity variation on the performance of the proposed architecture. I
SHIP2 inhibition modulates PI3K-AKT signaling and cell growth in eSCC preclinical models
info:eu-repo/semantics/nonPublishe
Better Together: Targeted Combination Therapies in Breast Cancer
Recent discoveries both in cell proliferation and survival mechanisms and new antineoplastic agents have led to deep change in the breast cancer treatment paradigm. Nonetheless, all of the progress in knowledge and strategy has not been enough to overcome mechanisms of escape and resistance put in place by the tumor cells. New targeted agents mean new possibilities for combinations, a viable option to try to stop compensatory pathways of tumor growth activated in response to therapeutics. The main challenges in designing a combined therapy come from the variety of subtypes of breast cancer (luminal A, luminal B, HER2-enriched, and basal-like) and from the multitude of pathways each subtype can exploit. Recent research has focused on dual blockade of HER2 (trastuzumab-lapatinib; trastuzumab-pertuzumab) and concomitant blockade of the endocrine driver and other pathways such as the PI3K/AKT/mTOR pathway (everolimus-exemestane), HER2 (trastuzumab/lapatinib-endocrine therapy) and the cell cycle through cyclin-dependent kinase inhibition (letrozole-palbociclib). This combined and personalized approach to treatment needs a profound knowledge of the mechanisms leading to proliferation in each tumor subtype. Deepening our understanding of tumor growth is mandatory to keep improving the efficacy of combination therapy. (C) 2015 Elsevier Inc. All rights reserved